NCT00385827 2014-08-20A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)Centocor, Inc.Phase 2 Terminated106 enrolled 13 charts
NCT00265135 2014-07-03A Study of CNTO 328 in Subjects With Metastatic Renal Cell CarcinomaCentocor, Inc.Phase 1/2 Completed68 enrolled
NCT00401765 2014-05-26A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate CancerCentocor, Inc.Phase 1 Completed40 enrolled